Investieren in die Zukunft von morgen.

weil viele werden schon bei 100% gewinn die abstoßen.
Ihr dürftet es nicht vergessen das hier auch viele Zocker drin sind.
Deswegen Geduld und Vernunft bringt uns weiter.
Aber ich bin zuversichtlich und hoffe wenn es los geht dann ziemlich schnell hoch.

http://www.ariva.de/cord_blood_amer_inc-aktie

habe auch nochmals aufgestockt jetzt 250k - reicht erstmal - in 2 Jahren schaue ich wieder
vorbei
bis denne  

bin ich auch dabei.  

im "Club der zukünftigen Millionäre"
 

Bei dem aktuellen Dollarkurs von 1,46 und einem Aktienwert von 0,0032$ entspricht das einem Eurokurs von 0,0022€.

Gekauft wird in Berlin fleisig zu 0,003€

Schmeißt ihr immer gerne 30% aus dem Fenster??  

alle Info´s sind in englisch, hat jemand mal aktuelle Zahlen parat.....über Verbindlichkeiten oder Gewinne


http://twitter.com/cbai  

http://www.ariva.de/cord_blood_amer_inc-aktie

bei den Beträgen kann das schon mal vorkommen

 

und ich wollte noch was nachlegen...

zuviele Lemminge laufen ins offene Messer....  

so wie ich das sehe hast du deine Million (Aktien) ja schon sicher
 

der Kurs von 0.003 ist bald Vergangenheit, denn wahrscheinlich kaufen die Amis gleich auch noch das ein oder andere cord blood Papier !  

was frei machen und aufstocken

...gehts richtig ab
 

hi alle erstmal, und onkelbrain schau mal op es dir hilft.

$1.6 Million in Debt Retired in Third Quarter 2009
Tuesday August 25, 2009, 5:00 am EDT

SANTA MONICA, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has retired $1.6 million in debt since July 2009. The Company previously announced it retired $5 million in debt in the first half of 2009.

"We have said that one of the pillars of strength for Cord Blood America in 2009 was to significantly reduce debt and we certainly are fulfilling this obligation to our shareholders," said Matthew Schissler, founder and CEO. The Company also announced on August 5, 2009, that it retired $2.53 million of long-term debt with the payoff of two notes with the Shelter Island Opportunity Fund.

"Retirement of debt is good for our balance sheet and makes CBAI a better investment for our shareholders," said Mr. Schissler. "We are pleased with a strengthened balance sheet, having recently announced second quarter results showing a significant increase in working capital and cash on hand."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate,'' "believe,'' "expect,'' "future,'' "intend,'' "plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

CONTACT:
Paul Knopick

E & E Communications
949/707-5365  

wenn du ein bischen rumgoogelst wirst du einiges von cord blood finden,
sogar auf you tube.

gut invest an alle  

http://finance.yahoo.com/q/is?s=cbai.ob  

Um an die richtigen " Mücken " zu kommen, sehe ich momentan folgende Papiere in meiner persönlichen Hitliste - keine Kaufempfehlung, nur eine nüchterne Betrachtung:

iq power : ist seriös, Zukunft gesichert, in 2 Jahren brummt der Laden wieder. Und momentan ist die Aktie sehr günstig ! 5 fach in einem Jahr möglich

cord blood: ist seriös, Zukunft gesichert und aussichtsreich, Aktie mega günstig. Kurs nach oben hin offen, alles ist möglich ! Aber es bedarf schon eine gewisse Zeit; das wird wohl noch 10 Jahre dauern, wenn man den Jackpot knacken will !

ecotality: seriös ? naja. Zukunft interessant. Momentan zu teuer. Aber bei 3 cent würde ich da reinbuttern . Hohes Risiko, aber bei 3 cent wird ne spitzen Chance geboten !

BKN biostrom: seriös ; Geld ist genug da; Zukunft soll spitze werden; Ab 1,80 kaufe ich diese Aktie wie Sau ! 5-fach in 2 Jahren möglich. Aber ansonsten eine recht sichere Anlage, da keine Aussicht auf Totalverlust, bzw. keine massiven Kursrütsche mehr.

Für weitere Vorschläge bin ich immer offen !

Los Brunetta, hau noch ein paar raus !

 

Bei IQ Power werden Unmengen an neuen Aktien auf den Markt geworfen, da wird die Verwässerung enorm.

Mal abwarten ;)  

und der Kurs ist bei 0,20-0,23€
Es wird noch zu steigerung kommen
http://www.4investors.de/php_fe/index.php?sektion=stock&ID=22579

Cord Blood America Nearing Completion of Construction of Las Vegas Laboratory; One of the Largest Cryogenic Storage Labs in U.S.
Thursday, 10 September 2009 06:00 Cord Blood America, Inc.



SANTA MONICA, Calif., Sept. 10 - Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, said today that it is on schedule to complete the construction of its new Las Vegas laboratory by the first week of October.

Matthew Schissler, founder and CEO, was interviewed by analyst Francis Gaskins. The entire interview is available at http://www.stoxrox.com/cbai-9-10-09.mp3 .

"Most of the equipment has been purchased and we are scheduled to begin processing our own stem cells in the near future," Mr. Schissler said in the interview. He said the new laboratory will:
Allow gross profit to increase greatly because the Company will no longer outsource and pay significant storage fees.
Allow Cord Blood to store tissues and samples for other companies.
Decrease transportation costs because the lab is near the large Las Vegas airport.
Allow for the storage of other stem cells such as adipose tissue and peripheral blood stem cells.
Prepare the Company for the future, with more medical uses of stem cells expected every year.

"This facility will perhaps be the largest cryogenic storage lab in the U.S. We believe adding business-to-business clients, and diversifying our income stream, will provide immediate returns for shareholders," Mr. Schissler said.

In the interview, Cord Blood America's CEO said $6.6 million in debt has been eliminated from the balance sheet so far this year and "we will continue to reduce debt as far and fast as possible. Shareholders should understand that once the debt is gone, the true valuation of the Company will emerge."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company’s performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com

Quelle: http://www.cordblood-america.com/Cord-Blood-America-News/cor…  

guter witz, deine quelle ist 1 jahr alt.

hier werden 300 Mio. (!) neue Namensaktien ausgegeben!  

0,0455 € übrigens.

die verwässerung wird gigantisch